Regulation of kallikrein-related peptidases in the skin - From physiology to diseases to therapeutic options

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 442-449

  Fischer, Jan ^a   Meyer Hoffert, Ulf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Atopic dermatitis; LEKTI; LL 37; Netherton syndrome; Proteinase activated receptor; Rosacea

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; APROTININ; KALLIKREIN 5; KALLIKREIN RELATED PEPTIDASE; MATRIPTASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; STROMELYSIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; HUMAN; IMMUNOREACTIVITY; KINETICS; LIQUEFACTION; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEINASE INHIBITION; SKIN EXFOLIATION; TRANSCRIPTION REGULATION;

ANTIMICROBIAL CATIONIC PEPTIDES; DERMATITIS, ATOPIC; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INHIBITORY CONCENTRATION 50; KALLIKREINS; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEOLYSIS; RECEPTOR, PAR-1; ROSACEA; SERPINS; SKIN; SKIN DISEASES; TISSUE DISTRIBUTION; TRANSCRIPTION, GENETIC;

EID: 84883230192     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-11-0836     Document Type: Article

References (81)

1. Pavlopoulou A, Pampalakis G, Michalopoulos I, et al. Evolutionary history of tissue kallikreins. PLoS ONE 2010; 5: e13781.
2. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391: 505-511.
3. Veveris-Lowe TL, Lawrence MG, Collard RL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005; 12: 631-643.
4. Oikonomopoulou K, Diamandis EP, Hollenberg MD. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. Biol Chem 2010; 391: 299-310.
5. Dong Y, Tan OL, Loessner D, et al. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res 2010; 70: 2624-2633.
6. Ekholm IE, Brattsand M, Egelrud T. Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process? J Invest Dermatol 2000; 114: 56-63.
7. Lundstrom A, Egelrud T. Stratum corneum chymotryptic enzyme: a proteinase which may be generally present in the stratum corneum and with a possible involvement in desquamation. Acta DermVenereol 1991; 71: 471-474.
8. Egelrud T. Desquamation in the stratum corneum. Acta DermVenereol 2000; 208: 44-45.
9. Stefansson K, Brattsand M, Ny A, et al. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol Chem 2006; 387: 761-768.
10. Eissa A, Amodeo V, Smith CR, et al. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem 2011; 286: 687-706.
11. Lundwall A, Brattsand M. Kallikrein-related peptidases. Cell Mol Life Sci 2008; 65: 2019-2038.
12. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
13. Komatsu N, Takata M, Otsuki N, et al. Expression and localisation of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 2003; 121: 542-549.
14. Komatsu N, Saijoh K, Toyama T, et al. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br J Dermatol 2005; 153: 274-281.
15. Nylander-Lundqvist E, Back O, Egelrud T. IL-1 beta activation in human epidermis. J Immunol 1996; 157: 1699-1704.
16. Yao C, Karabasil MR, Purwanti N, et al. Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1beta in the submandibular gland of mice. J Biol Chem 2006; 281: 7968-7976.
17. Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006; 20: 2068-2080.
18. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13: 975-980.
19. Meyer-Hoffert U, Schroder JM. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 2011; 15: 16-23.
20. Shaw JL, Diamandis EP. Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines. Biol Chem 2008; 389: 1409-1419.
21. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 178: 2229-2240.
22. Komatsu N, Saijoh K, Kuk C, et al. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br J Dermatol 2007; 156: 875-883.
23. Voegeli R, Rawlings AV, Breternitz M, et al. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br J Dermatol 2009; 161: 70-77.
24. Voegeli R, Doppler S, Joller P, et al. Increased mass levels of certain serine proteases in the stratum corneum in acute eczematous atopic skin. Int J Cosmet Sci 2011; 33: 560-565.
25. Morizane S, Yamasaki K, Kabigting FD, et al. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J Invest Dermatol 2010; 130: 1297-1306.
26. Kawasaki S, Kawamoto S, Yokoi N, et al. Up-regulated gene expression in the conjunctival epithelium of patients with Sjogren's syndrome. Exp Eye Res 2003; 77: 17-26.
27. Yoon H, Blaber SI, Debela M, et al. A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15. Biol Chem 2009; 390: 373-377.
28. Yoon H, Laxmikanthan G, Lee J, et al. Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem 2007; 282: 31852-31864.
29. Beaufort N, Plaza K, Utzschneider D, et al. Interdependence of kallikrein-related peptidases in proteolytic networks. Biol Chem 2010; 391: 581-587.
30. Yoon H, Blaber SI, Li W, et al. Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases. Biol Chem 2013; 394: 137-147.
31. Ohler A, Debela M, Wagner S, et al. Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation. Biol Chem 2010; 391: 455-460.
32. Sales KU, Masedunskas A, Bey AL, et al. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat Genet 2010; 42: 676-683.
33. Blaber M, Yoon H, Juliano MA, et al. Functional intersection of the kallikreinrelated peptidases (KLKs) and thrombostasis axis. Biol Chem 2010; 391: 311-320.
34. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline Indirectly Inhibits Proteolytic Activation of Tryptic Kallikrein-Related Peptidases and Activation of Cathelicidin. J Invest Dermatol 2012; 132: 1435-1442.
35. Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res 2011; 63: 130-145.
36. Memari N, Jiang W, Diamandis EP, et al. Enzymatic properties of human kallikrein-related peptidase 12 (KLK12). Biol Chem 2007; 388: 427-435.
37. Borgono CA, Michael IP, Shaw JL, et al. Expression and functional characterisation of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007; 282: 2405-2422.
38. Bayes A, Tsetsenis T, Ventura S, et al. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem 2004; 385: 517-524.
39. Hachem JP, Houben E, Crumrine D, et al. Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 2006; 126: 2074-2086.
40. Goettig P, Magdolen V, Brandstetter H. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 2010; 92: 1546-1567.
41. Kaiserman D, Whisstock JC, Bird PI. Mechanisms of serpin dysfunction in disease. Expert Rev Mol Med 2006; 8: 1-19.
42. Farshchian M, Kivisaari A, Ala-Aho R, et al. Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol 2011; 179: 1110-1119.
43. Hoffmann DC, Textoris C, Oehme F, et al. Pivotal role for alpha1-antichymotrypsin in skin repair. J Biol Chem 2011; 286: 28889-28901.
44. Krebs M, Uhrin P, Vales A, et al. Protein C inhibitor is expressed in keratinocytes of human skin. J Invest Dermatol 1999; 113: 32-37.
45. Zhang C, Li X, Lian X, et al. Immunolocalisation of protein C inhibitor in differentiation of human epidermal keratinocytes. Acta Histochem 2007; 109: 461-467.
46. Providence KM, Higgins PJ. PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. J Cell Physiol 2004; 200: 297-308.
47. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25: 141-142.
48. Comel M. Dermatologica 1949; 98: 133-136.
49. Netherton EW. A unique case of trichorrhexis nodosa; bamboo hairs. AMA Arch Derm 1958; 78: 483-487.
50. Bitoun E, Micheloni A, Lamant L, et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet 2003; 12: 2417-2430.
51. Egelrud T, Brattsand M, Kreutzmann P, et al. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br J Dermatol 2005; 153: 1200-1203.
52. Descargues P, Deraison C, Bonnart C, et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet 2005; 37: 56-65.
53. Hachem JP, Wagberg F, Schmuth M, et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol 2006; 126: 1609-1621.
54. Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009; 206: 1135-1147.
55. Briot A, Lacroix M, Robin A, et al. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol 2010; 130: 2736-2742.
56. Furio L, Hovnanian A. When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition. J Invest Dermatol 2011; 131: 2169-2173.
57. Mitsudo K, Jayakumar A, Henderson Y, et al. Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry 2003; 42: 3874-3881.
58. Jayakumar A, Kang Y, Mitsudo K, et al. Expression of LEKTI domains 6-9' in the baculovirus expression system: recombinant LEKTI domains 6-9' inhibit trypsin and subtilisin A. Protein Expr Purif 2004; 35: 93-101.
59. Schechter NM, Choi EJ, Wang ZM, et al. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem 2005; 386: 1173-1184.
60. Kreutzmann P, Schulz A, Standker L, et al. Recombinant production, purification and biochemical characterisation of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 803: 75-81.
61. Deraison C, Bonnart C, Lopez F, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 2007; 18: 3607-3619.
62. Borgono CA, Michael IP, Komatsu N, et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 2007; 282: 3640-3652.
63. Fortugno P, Bresciani A, Paolini C, et al. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J Invest Dermatol 2011; 131: 2223-2232.
64. Fortugno P, Furio L, Teson M, et al. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis. Hum Mol Genet 2012; 21: 4187-4200.
65. Meyer-Hoffert U, Wu Z, Schroder JM. Identification of lympho-epithelial Kazaltype inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS ONE 2009; 4: e4372.
66. Brattsand M, Stefansson K, Hubiche T, et al. SPINK9: A Selective, Skin-Specific Kazal-Type Serine Protease Inhibitor. J Invest Dermatol 2009; 129: 1656-1665.
67. Brannstrom K, Ohman A, von Pawel Rammingen U, et al. Characterisation of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis. Biol Chem 2012; 393: 369-377.
68. Reiss K, Meyer-Hoffert U, Fischer J, et al. Expression and regulation of murine SPINK12, a potential orthologue of human LEKTI2. Exp Dermatol 2011; 20: 905-910.
69. Meyer-Hoffert U, Wu Z, Kantyka T, et al. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. J Biol Chem 2010; 285: 32174-32181.
70. Kantyka T, Fischer J, Wu Z, et al. Inhibition of Kallikrein-related Peptidases by the Serine Protease Inhibitor of Kazal-type 6. Peptides 2011; 32: 1187-1192.
71. Lu H, Huang J, Li G, et al. Expression, purification and characterisation of recombinant human serine proteinase inhibitor Kazal-type 6 (SPINK6) in Pichia pastoris. Protein Expr Purif 2012; 82: 144-149.
72. Bennett K, Callard R, Heywood W, et al. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI. J Proteome Res 2010; 9: 4289-4294.
73. Fischer J, Koblyakova Y, Latendorf T, et al. Cross-Linking of SPINK6 by Transglutaminases Protects from Epidermal Proteases. J Invest Dermatol 2013; epub ahead of print.
74. Drenth JP, R, Jansen JB. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis. Gut 2002; 50: 687-692.
75. Schalkwijk J, Wiedow O, Hirose S. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J 1999; 340: 569-577.
76. Bonnart C, Deraison C, Lacroix M, et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J Clin Invest 2010; 120: 871-882.
77. Franzke CW, Baici A, Bartels J, et al. Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. J Biol Chem 1996; 271: 21886-21890.
78. Delaria KA, Muller DK, Marlor CW, et al. Characterisation of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 1997; 272: 12209-12214.
79. Bugge TH, List K, Szabo R. Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front Biosci 2007; 12: 5060-5070.
80. Mukai S, Fukushima T, Naka D, et al. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. Febs J 2008; 275: 1003-1017.
81. Swedberg JE, de Veer SJ, Harris JM. Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia. Biol Chem 2010; 391: 357-374.